Skip to content
lifestyle.celebhomes.net
Author:
Vaxcyte, Inc.
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
May 8, 2026
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
March 18, 2026
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
February 6, 2026
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 2, 2026
←
Previous Page
1
2